S100A5 and urinary bladder cancer: Systematic multi‐omics analysis identifies S100A5 as a novel immunosuppressive target for bladder cancer, which shapes a non‐inflamed tumor microenvironment in bladder cancer by inhibiting the secretion of pro‐inflammatory chemokines and the recruitment and cytotoxicity of CD8+ T cells.